CPRX Dec 2024 17.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:02PM EDT. Market open.
Loading interactive chart…
- Zacks
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?
Most readers would already know that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased by 4.1% over the past...
- GlobeNewswire
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampr
© 2024 Yahoo. All rights reserved.